BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsEarnings

Conference Call to be Held at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Apr. 23, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today

Open original release

Related news

XERSXeris Pharmaceuticals2026-05-07 11:00 EST

Xeris Biopharma Reports First Quarter 2026 Financial Results

ABOSAcumen Pharmaceuticals2026-05-05 20:00 EST

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

HRMYHarmony Biosciences2026-04-23 12:05 EST

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

ALKSAlkermes plc2026-04-21 20:05 EST

Alkermes to Report First Quarter Financial Results on May 5, 2026

AXSMAxsome2026-04-08 11:00 EST

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

AXSMAxsome2026-07-14 11:00 EST

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

ABOSAcumen Pharmaceuticals2026-05-12 11:00 EST

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

View all latest news

Xeris Pharmaceuticals

Xeris Pharmaceuticals is a specialty pharmaceutical company focused on injectable and liquid formulations for endocrine, neurologic, and gastrointestinal conditions. Its commercial base is tied to product delivery and convenience.

Recent company news

XERSXeris Pharmaceuticals2026-05-07 11:00 EST

Xeris Biopharma Reports First Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-04-23 11:30 EST

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

XERSXeris Pharmaceuticals2026-04-03 20:15 EST

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

XERSXeris Pharmaceuticals2026-03-02 12:00 EST

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

XERSXeris Pharmaceuticals2026-02-26 22:55 EST

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Stock data

Close
8.21 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States